2023
Atrial Fibrillation And Conduction Disease Are Associated With Cardiac Amyloidosis Subtypes
Patolia H, Chandramouli S, Cavalier J, Sen S, Arps K, Pokorney S, Karra R, Khouri M. Atrial Fibrillation And Conduction Disease Are Associated With Cardiac Amyloidosis Subtypes. Journal Of Cardiac Failure 2023, 29: 550-551. DOI: 10.1016/j.cardfail.2022.10.014.Peer-Reviewed Original ResearchAtrial fibrillationConduction diseaseVentricular tachycardiaCardiac amyloidosisHigh prevalencePresence of AFCross-sectional observational studyRight bundle branch blockHeart failure symptomsResults Patient characteristicsStandardized chart reviewSubtypes/genotypesPrevalence of arrhythmiasBundle branch blockLonger QRS intervalGenotype-related differencesATTR-CA patientsCardiac amyloidosis subtypesATTR-CMBaseline characteristicsChart reviewPatient characteristicsVentricular arrhythmiasAtrial arrhythmiasInfiltrative disease
2021
Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial
Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, Leifer ES, Felker GM, Fiuzat M, O’Connor C, Januzzi JL, Friedman DJ, Desai NR, Ahmad T, Freeman JV. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. Mayo Clinic Proceedings Innovations Quality & Outcomes 2021, 5: 447-455. PMID: 33997640, PMCID: PMC8105522, DOI: 10.1016/j.mayocpiqo.2021.02.005.Peer-Reviewed Original ResearchNT-proBNP levelsReduced ejection fractionAtrial fibrillationHF hospitalizationHeart failureEjection fractionMedical therapyN-terminal pro-B-type natriuretic peptideOptimal guideline-directed medical therapyPro-B-type natriuretic peptideGuideline-directed medical therapyHigher NT-proBNP concentrationsHigher NT-proBNP levelsGUIDE-IT trialMedical therapy useHeart failure outcomesHeart Failure TrialPrevalent atrial fibrillationNT-proBNP concentrationsType natriuretic peptideEvidence-based therapiesCardiovascular deathAF patientsTherapy useFailure Trial